NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose.
DA-1726 Phase 1 IND Filing Expected by Year End 2023
Board Strengthened with Recent Appointment of Industry Veteran, James P. Tursi, M.D.
Cash and Cash Equivalents of $25.8 Million, Expected to Fund.
Lollitests: Verzögert sich der Start an Würzburger Schulen? mainpost.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mainpost.de Daily Mail and Mail on Sunday newspapers.